[Advances in Patient Derived Tumor Xenograft (PDTX) Model from Lung Cancer]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2017 Oct 25

PMID 29061220

Citations 1

Authors

Baodong Qin

Xiaodong Jiao

Lingyan Yuan

Ke Liu

Yuansheng Zang

Affiliations

Soon will be listed here.

Abstract

With the development of tumor molecular biology and genomics, it has been recognized that there are great heterogeneity in the biological characteristics, molecular typing and reactivity of the same tumor species among different individuals. In order to achieve true tumor individualized and precise therapy, a new concept of human tumor tissue xenograft model (patient derived tumor xenograft, PDTX) is proposed. The previous study has revealed that PDTX model can truly reflect the biological characteristics of tumor tissue and drug efficacy. And PDTX model could be used to select individual chemotherapy regime, evaluate drug resistance and explore efficacy and safety of new drug. PDTX model has been used in clinical practice of several type of cancer including lung cancer. In this paper, the current research progress of lung cancer PDTX is reviewed.

Citing Articles

Preclinical Models for Functional Precision Lung Cancer Research.

Yu J, Kiss Z, Ma W, Liang R, Li T Cancers (Basel). 2025; 17(1.

PMID: 39796653 PMC: 11718887. DOI: 10.3390/cancers17010022.

Establishment of a non-small-cell lung cancer-liver metastasis patient-derived tumor xenograft model for the evaluation of patient-tailored chemotherapy.

Yang X, Meng G Biosci Rep. 2019; 39(7).

PMID: 31221816 PMC: 6609754. DOI: 10.1042/BSR20182082.

References

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A . Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008; 14(20):6456-68. DOI: 10.1158/1078-0432.CCR-08-0138. View

Fu S, Zhao J, Bai H, Duan J, Wang Z, An T . High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies. Thorac Cancer. 2016; 7(1):100-10. PMC: 4718126. DOI: 10.1111/1759-7714.12291. View

Ma Y, Zhang P, An G, Zhang X, Zhang L, Si J . Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients. Med Sci Monit. 2016; 22:4017-4025. PMC: 5087670. DOI: 10.12659/msm.900661. View

Lee H, Lee J, Lee S, Cho H, Song H, Jeong D . Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin Cancer Res. 2015; 21(5):1172-82. DOI: 10.1158/1078-0432.CCR-14-1589. View

Wang D, Pham N, Tong J, Sakashita S, Allo G, Kim L . Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer. 2016; 140(3):662-673. DOI: 10.1002/ijc.30472. View

Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T . Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004; 40(2):298-307. DOI: 10.1016/j.ejca.2003.10.011. View

Nakajima T, Geddie W, Anayama T, Ko H, da Cunha Santos G, Boerner S . Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Lung Cancer. 2015; 89(2):110-4. DOI: 10.1016/j.lungcan.2015.05.018. View

Zhang X, Zhang J, Li M, Huang X, Yang X, Zhong W . Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J Transl Med. 2013; 11:168. PMC: 3716998. DOI: 10.1186/1479-5876-11-168. View

Valtorta S, Moro M, Prisinzano G, Bertolini G, Tortoreto M, Raccagni I . Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response. J Nucl Med. 2016; 58(1):42-47. DOI: 10.2967/jnumed.116.176404. View

10.

Roife D, Kang Y, Wang L, Fang B, Swisher S, Gershenwald J . Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery. 2017; 161(5):1246-1254. PMC: 5404969. DOI: 10.1016/j.surg.2016.11.020. View

11.

Ledford H . US cancer institute to overhaul tumour cell lines. Nature. 2016; 530(7591):391. DOI: 10.1038/nature.2016.19364. View

12.

Hao C, Wang L, Peng S, Cao M, Li H, Hu J . Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2014; 357(1):179-185. PMC: 4301580. DOI: 10.1016/j.canlet.2014.11.024. View

13.

Merk J, Rolff J, Dorn C, Leschber G, Fichtner I . Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?. Eur J Cardiothorac Surg. 2011; 40(1):e29-33. DOI: 10.1016/j.ejcts.2011.02.010. View

14.

Anderson W, Boyd M, Aguilar J, Pickell B, Laysang A, Pysz M . Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. PLoS One. 2015; 10(5):e0125255. PMC: 4425530. DOI: 10.1371/journal.pone.0125255. View

15.

Stewart E, Mascaux C, Pham N, Sakashita S, Sykes J, Kim L . Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. J Clin Oncol. 2015; 33(22):2472-80. DOI: 10.1200/JCO.2014.60.1492. View

16.

Derose Y, Wang G, Lin Y, Bernard P, Buys S, Ebbert M . Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011; 17(11):1514-20. PMC: 3553601. DOI: 10.1038/nm.2454. View

17.

Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F . Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012; 18(24):6658-67. DOI: 10.1158/1078-0432.CCR-12-2694. View

18.

Cutz J, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M . Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res. 2006; 12(13):4043-54. DOI: 10.1158/1078-0432.CCR-06-0252. View

19.

Tentler J, Tan A, Weekes C, Jimeno A, Leong S, Pitts T . Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338-50. PMC: 3928688. DOI: 10.1038/nrclinonc.2012.61. View

20.

Pearson A, Smyth E, Babina I, Herrera-Abreu M, Tarazona N, Peckitt C . High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discov. 2016; 6(8):838-851. PMC: 5338732. DOI: 10.1158/2159-8290.CD-15-1246. View